Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

BACKGROUND: Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first choice in rheumatoid arthritis (RA) but response varies. Predicting non-response to MTX could enable earlier access to alternative or additional medications and control of disease progression. We aimed to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Sergeant, Jamie C., Hyrich, Kimme L., Anderson, James, Kopec-Harding, Kamilla, Hope, Holly F., Symmons, Deborah P. M., Barton, Anne, Verstappen, Suzanne M. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044018/
https://www.ncbi.nlm.nih.gov/pubmed/30005689
http://dx.doi.org/10.1186/s13075-018-1645-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044018/
https://www.ncbi.nlm.nih.gov/pubmed/30005689
http://dx.doi.org/10.1186/s13075-018-1645-5

Ejemplares similares